Releasing the Brake on Oncolytic Viral Therapy
Clare Y. Slaney1,2 and Phillip K. Darcy1,2,3,4

Oncolytic virus that selectively targets and eradicates tumor cells and immune checkpoint blockade that unleashes host antitumor immune responses show synergistic effects against cancer. This combination holds great promise for future treatment of a broad range of cancers in patients. Clin Cancer Res 21(24), 5417–9. ©2015 AACR.

See related article by Rojas et al., p. 5543

Published OnlineFirst September 16, 2015; DOI: 10.1158/1078-0432.CCR-15-1769

In this issue of Clinical Cancer Research, Rojas and colleagues report that combining an oncolytic virus and the immune checkpoint blockade inhibitor anti–CTLA-4 resulted in significantly better antitumor responses than either modality alone in two different mouse tumor models (1). These two therapies work in different ways. The oncolytic virus is tumor-selective due to specific deletion of genes that are crucial for replication of the virus in normal cells but dispensable in cancer cells (2). The immune checkpoint inhibitor, an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), was the first drug of this kind approved by the FDA for treatment of cancer patients. CTLA-4 is exclusively expressed on T cells and regulates the amplitude of early T-cell activation (3). In this study, the authors revealed that administration of oncolytic virus and anti–CTLA-4 antibody resulted in activation of both innate and adaptive immune responses against the tumor and blocked immunosuppressive mechanisms within the tumor microenvironment.

The ability of viruses to lyse cancer cells has been well recognized. Genetically modified oncolytic viruses, such as herpes, vaccinia, and reovirus, have demonstrated encouraging results against cancers in both mouse models and human trials (2). Administration of talimogene laherparepvec (T-VEC) in human melanoma trials in particular has demonstrated encouraging responses at both the injected and distant tumor sites, including visceral lesions. T-VEC is a genetically modified herpes type 1 oncolytic virus that contains an insertion of the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene that promotes local antigen presentation and systemic antitumor immunity (4). A similar approach using the vaccinia virus, JX-594, containing GM-CSF and deletion of the thymidine kinase gene has also generated therapeutic responses in patients with advanced hepatocellular carcinoma, and these responses were also observed at distant untreated tumor sites (5).

However, despite these reports, the overall clinical benefit of oncolytic viruses as a monotherapy has been rather modest, and only a proportion of patients have benefited from this therapy. This may be due to the hostile tumor microenvironment that blocks viral induced antitumor immunity. Therefore, combining oncolytic viral therapy with approaches such as immune checkpoint blockade therapy that may release the brake on immune responses within the tumor microenvironment is a rational strategy. The application of oncolytic virus can induce strong infiltration of innate immune cells to the tumor microenvironment and promote the release of tumor antigens resulting in priming of an adaptive immune response against the tumor (Fig. 1). However, the immunoregulatory tumor microenvironment can effectively dampen effector T-cell responses induced by oncolytic viruses against the tumor resulting in immune escape. This may be overcome by administration of immune checkpoint inhibitors.

Immune checkpoint blockade has shown great promise for boosting immune responses against cancer by blocking checkpoint molecules on T cells and other effector immune cells. Two of the most studied immune checkpoint receptors are CTLA-4 and programmed cell death protein 1 (PD-1). These two receptors are both inhibitory but regulate immune responses by different mechanisms. CTLA-4 is exclusively expressed on T cells where it regulates the amplitude of early T-cell activation following binding to its ligands CD80 or CD86. The administration of anti–CTLA-4 antibody results in activation of effector T cells and depletion of regulatory T cells in the tumor that express high levels of CTLA-4 (6). In contrast, PD-1 expression is induced only when T cells become activated and its engagement with its ligands PD-L1 or PD-L2 inhibits kinases that are involved in T-cell activation. The use of either of these antibodies in the clinic has generated significant outcomes in a proportion of cancer patients, and recently the combination of these two drugs demonstrated significant advantage over either drug alone in patients with advanced melanoma (7). In a recent study, Victor and colleagues demonstrated that PD-1 and CTLA-4 blockade worked in a nonredundant way and combining the dual blockade with localized radiation generated synergistic antitumor effects (8). This study also highlighted the fact that the success of checkpoint blockade therapy is dependent in part on an ongoing immune response present within the tumor microenvironment. Thus, the combination of checkpoint inhibitors with approaches that can induce antitumor immune responses is an exciting area of clinical investigation.
responses \textit{de novo}, such as oncolytic viruses, is anticipated to further increase treatment efficacy \cite{1, 9}. The work undertaken by Rojas and colleagues utilized the oncolytic B18R-vaccinia virus that contains the deletion of thymidine kinase, an enzyme necessary for nucleic acid metabolism, and B18R, a gene encoding for the decoy receptor for type I interferons. The deletion of these two genes restricts the ability of the virus to replicate and spread within tumors, in preference to normal tissues. When B18R-vaccinia virus was given to mice followed by the administration of anti–CTLA-4 4 days later, antitumor effects were greatly improved compared with administration of virus alone. The enhanced therapeutic activity was accompanied by enhanced infiltration of CD8$^+$ and CD4$^+$ T cells, natural killer T cells, and natural killer cells into the tumor site. Interestingly, when the two components were given simultaneously, innate cells, including natural killer (NK) and natural killer T (NKT) cells, are recruited to the inflammatory tumor bed that may further contribute to antitumor immune responses, through secretion of cytokines such as IFN$\gamma$. The activated T cells traffic to the tumor site and react against cancer cells through recognition of MHC/peptide complexes. Administration of CTLA-4 antibody may further contribute to increasing T-cell activity at the tumor site. MDSC, myeloid-derived suppressor cell; TCR, T-cell receptor.

In the clinic, the combination of Ipilimumab (monoclonal antibody to CTLA-4) and T-VEC is currently being tested in a phase III trial to treat advanced melanoma patients. The preliminary data are promising, demonstrating a significant synergistic effect \cite{11}. A further trial involving the checkpoint blocking antibody anti–PD-1 with oncolytic virus is planned for the treatment of melanoma patients \cite{11}. Whether this combined therapy leads to better control of distal tumor metastases remains to be seen. In summary, the combination of oncolytic virus and anti–CTLA-4 therapy appears to hold great promise for controlling cancer progression in patients and also opens up new options for
combining oncolytic virus with other immunomodulatory therapies. Additional approaches that amplify and prolong antitumor immune responses such as the agonist antibody anti-CD137 have been shown to effectively combine with oncolytic virus to significantly reduce tumor growth and metastases in mouse models (12). The insertion of genes into the oncolytic virus such as chemokines and cytokines for enhancing adaptive immune responses, and genes for targeting vasculature, angiogenesis, VEGF, and tumor stroma, have all been tested to enhance the oncolytic virus efficacy against cancer (2). Clearly, increased understanding of the interactions between oncolytic virus and host antitumor immunity will help in the design of more effective combination strategies for treatment of cancer in patients.

**Disclosure of Potential Conflicts of Interest**
No potential conflicts of interest were disclosed.

**Authors’ Contributions**
Conception and design: C.Y. Slaney, P.K. Darcy
Writing, review, and/or revision of the manuscript: C.Y. Slaney, P.K. Darcy

**Grant Support**
C.Y. Slaney was supported by a National Breast Cancer Fellowship (PF-12-14). P.K. Darcy was supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (1041828).

Received August 17, 2015; accepted August 19, 2015; published OnlineFirst September 16, 2015.

**References**
Clinical Cancer Research

Releasing the Brake on Oncolytic Viral Therapy

Clare Y. Slaney and Phillip K. Darcy


Updated version
Access the most recent version of this article at:

Cited articles
This article cites 12 articles, 5 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/21/24/5417.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.